Radiotherapy News and Research

RSS

Radiation therapy (in North America), or radiotherapy (in the UK and Australia) also called radiation oncology, and sometimes abbreviated to XRT, is the medical use of ionizing radiation as part of cancer treatment to control malignant cells (not to be confused with radiology, the use of radiation in medical imaging and diagnosis).

Access Pharmaceuticals to present MuGard clinical data at 2010 MASCC conference

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it will present data from the ongoing work involving its lead product, MuGard, and host an oral mucositis symposium at the MASCC conference being held in Vancouver, B.C. on June 24-26, 2010. MuGard is Access Pharma's FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments.

22 Apr 2010

Cloud computing solution may help treat cancer

Cloud services provided over grid technology are helping to treat cancer patients, thanks to an enormous effort by European researchers working closely with industry.

21 Apr 2010

New treatment modalities for RCC

Renal cell carcinoma accounts for about 3% of all solid tumours in adults, and worldwide, more than 200.000 new cases and 100.000 deaths result each year from this malignancy.

21 Apr 2010

Study to assess and cut down on radiation exposure in cancer patients

Researchers are trying to assess and reduce the amount of radiation that Australian cancer patients are currently exposed to.

20 Apr 2010

Surgery still the only measure to cure RCC

Renal cell carcinoma (RCC) accounts for about 3% of all solid tumours in adults, and worldwide, more than 200.000 new cases and 100.000 deaths result each year from this malignancy.

19 Apr 2010

Radiolabeled hedgehog can differentiate stem-like cancer cells, identify aggressive tumors

At the American Association for Cancer Research 101st Annual Meeting 2010, scientists and clinicians will present more than 6,300 abstracts dealing with innovative aspects of biology, technology and emerging therapies.

19 Apr 2010

Strativa Pharmaceuticals: Oravig buccal tablets receive FDA approval for OPC

Strativa Pharmaceuticals today announced that the U.S. Food and Drug Administration has approved Oravig (miconazole) buccal tablets for the treatment of oropharyngeal candidiasis, more commonly known as thrush, in adults and children age 16 and older.

17 Apr 2010

FDA approves BioAlliance Pharma's Oravig for OPC

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, announces today the approval by the US FDA of Oravig® (miconazole Lauriad®, known as Loramyc® in Europe) for the treatment of Oropharyngeal Candidiasis (OPC) in adults.

17 Apr 2010

University Hospital of Zurich treats cancer patients with Varian Medical Systems' TrueBeam system

The University Hospital of Zurich has become the first medical center in the world to commence treating cancer patients with the revolutionary TrueBeam system from Varian Medical Systems, a new platform for image-guided radiotherapy and radiosurgery that was designed from the ground up to treat a moving target with unprecedented speed and precision.

16 Apr 2010

Rudd announces funds for north coast NSW cancer centers

Prime Minister Kevin Rudd had announced a regional cancer center in the mid-north coast on Tuesday at Port Macquarie. He says plans are underway to invest almost $5 million for a second linear accelerator at the Port Base Hospital.

16 Apr 2010

ErbB3 program development candidate selection triggers $5M milestone payment to AVEO Pharmaceuticals

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received a $5 million milestone payment from Biogen Idec International GmbH, a subsidiary of Biogen Idec, Inc., for the selection of the first humanized antibody development candidate from its ErbB3 program.

15 Apr 2010

Despite international guidelines, wide variations exist in breast cancer care

A global study of nearly 10,000 women with early breast cancer has found wide variations in how they were treated, despite international consensus on best practice, according to the May issue of the British Journal of Surgery.

13 Apr 2010

EDAP's Sonolith i-move lithotripter receives European approval

EDAP TMS SA, the global leader in therapeutic ultrasound, announced today the European approval of its new lithotripter, the Sonolith i-move. The EDAP sales team and distributors will begin marketing Sonolith i-move immediately and will officially introduce the product to distributors, partners and visiting urologists at the European Association Urology (EAU) congress, Booth #14, from April 17-19, 2010 in Barcelona, Spain.

12 Apr 2010

Global study shows wide variations in treatment of women with early breast cancer

12 Apr 2010

Patients with end-stage cancer do not benefit from palliative radiotherapy: CANCER

A new analysis has found that a considerable proportion of patients with end-stage or terminal cancer do not benefit from palliative radiation therapy despite spending most of their remaining life undergoing treatments. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that greater efforts are needed to tailor appropriately palliative radiotherapy to patients with end-stage cancer.

12 Apr 2010

Saint Mary's and Sierra Neurosurgery Group partner to create Nevada's first Brain Tumor Center

Saint Mary's and Sierra Neurosurgery Group have partnered to create the region's first Brain Tumor Center in an effort to speed up the time between diagnosis and treatment.

8 Apr 2010

Oraya Therapeutics' IRay stereotactic radiotherapy system granted European CE Mark approval

Oraya Therapeutics, Inc. announces today that a leading European notified body has granted approval to designate the CE mark to Oraya's IRayTM stereotactic radiotherapy system. Under development since 2007, the IRay is designed specifically to treat diseases of the eye, and the technology enables precise delivery of low energy X-rays for the treatment of wet age-related macular degeneration (AMD).

8 Apr 2010